Sun Pharma says 2008 US growth will be 25%

India's Sun Pharmaceuticals is focusing ever more on the difficult US market, even as its contemporaries spread their risk away from the troubled area, according to a report by the US Business Standard.

Sun's US sales rocketed to reach 41% of the firm's annual revenues in 2008, from only 2% in 2000. Sun now expects growth in the region to reach 25%, exceeding the 18%-20% projection it has given for other markets including India.

Dilip Shanghvi, chairman of Sun, told the Business Standard that the USA still offers the best growth platform for the company. "The US is a large market, where a meaningful generic player can generate several billion dollars as revenues. We are far away from that. Rather than diffusing our energy in other markets, we want to concentrate on this market," Mr Shanghvi said.